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Abstract
Purpose: Throughout the world, illicit drug use continues to pose a 
significant risk to public health. The opioid crisis in North America, 
the diversion of the prescription drug tramadol throughout Africa, and 
the increasing supply of methamphetamines in East and South Asia all 
contribute to increasing risks to individual and societal health. 
Furthermore, the violation of human rights in efforts to enforce 
prohibitionist values poses significant threats to many individuals 
worldwide. With these evolving situations, it is imperative that 
researchers direct their attention to the various populations of illicit 
drug users. However, the inclusion of illicit drug users, often 
considered a vulnerable population, as participants in research studies 
presents several increased risks that must be addressed in study 
protocols. Researchers are required to provide “additional safeguards” to 
all study protocols involving illicit drug users, but there is often 
substantial variability and inconsistency in how these safeguards are 
applied. Additional safeguards can be timely, costly, and unduly 
burdensome for researchers, ethical review boards, and research 
participants. 
Approach: Through synthesis of the current literature, this article 
addresses the barriers to studying illicit drug users and the methods 
researchers can utilize to minimize risk. A case study is provided to 
illustrate the high level of scrutiny of study protocols involving the 
participation of illicit drug users and the effect of such scrutiny on 
recruitment of participants. The article concludes with a discussion of 
the effects of the current political climate on the recruitment of Au
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illicit drug users in research.
Conclusions: Individuals who participate in criminal or illegal behaviors 
such as illicit drug use, prostitution, illegal entry into a country, and 
human trafficking are susceptible to multiple physical, mental, and 
social health risks, as well as criminal prosecution. The importance of 
research on the health of marginalized populations cannot be overstated. 
This work must continue, and at the same time, we must continue to 
protect these individuals to the best of our ability through diligent 
attention to sound research methods.
Clinical Relevance: The use of illicit drugs continues to pose a 
substantial threat to global health. Individuals who use illicit drugs 
are susceptible to multiple physical, mental, and social health risks, as 
well as criminal prosecution. It is imperative that researchers study 
these vulnerable populations in order to develop interventions to 
minimize individual and societal harm. There are several barriers to the 
study of illicit drug users that must be addressed through rigorous 
methodology and the addition of safeguards. 
Journal of Nursing Scholarship, 51:4, ©2019 Sigma Theta Tau 
International.
Body of article:
An estimated 275 million individuals worldwide, or 5.6% of the 
global population 16 to 54 years of age, used an illicit drug at least 
once in 2016 (United Nations Office on Drugs and Crime [UNODC], 2018). An 
estimated 450,000 individuals died as a result of their drug use; 167,750 
directly from drug use disorders (mostly overdose), and the remainder 
from drug use–related illnesses such as hepatitis C virus (HCV) and human 
immunodeficiency virus (HIV). Cannabis continues to be the most widely 
used illicit substance, with an estimated 192 million users worldwide, 
while opioids continue to cause the most harm, accounting for 76% of drug 
use disorder–related deaths. The opioid crisis in North America has 
reached epidemic proportions, and has rightfully received international 
attention. However, other regions around the world have also been 
affected by supply-driven expansion of drug markets. In parts of Africa Au
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and Asia, illicit use of the opioid tramadol is increasing at alarming 
rates. In East and Southeast Asia, the increased trafficking of 
methamphetamines poses a significant threat to the health and security of 
the population in that region. This growing public health problem in 
underdeveloped countries is under-researched and has gone largely 
unnoticed. People who inject drugs (PWIDs), an estimated 15.6 million 
individuals worldwide, continue to sustain the greatest health risks; 
more than half have been exposed to HCV and one in six lives with HIV 
(Degenhardt et al., 2017).
Of significant concern to public health providers is the lack of 
services for those experiencing substance use disorders (SUDs). Only one 
in six individuals with SUDs received any treatment for those disorders 
in 2016 (UNODC, 2018). Furthermore, access to evidence-based harm 
reduction strategies such as opioid substitution therapy (OST) varies by 
geographic location, ranging from 90% of PWIDs in the United Kingdom 
having access to OST, to none in the Russian Federation, where OST is not 
allowed (Mathers et al., 2010). These disparities create significant 
barriers to treatment. While OST is endorsed by the Joint United Nations 
Program on HIV/AIDS, the UNODC, and the World Health Organization (2009), 
many developing countries question this therapy and instead continue to 
promote abstinence-only treatment goals, frequently violating human 
rights (Jurgens, Csete, Amon, Baral, & Beyrer, 2010). 
Finally, while international treaties such as the Single Convention 
on Narcotic Drugs of 1961 as amended by the 1972 Protocol, the Convention 
on Psychotropic Substances of 1971, and the United Nations Convention 
against Illicit Traffic in Narcotic Drugs and Psychotropic Substances of 
1988 provided guidance for the scheduling and prohibition of psychotropic 
substances, enforcement of these policies varies greatly among nation 
states. For example, Uruguay, Canada, and 10 U.S. states have legalized 
the possession and retail sale of cannabis; Spain, Mexico, and the 
Netherlands have allowed for personal possession of cannabis; but in 
Malaysia, cannabis possession of over 7 ounces is considered trafficking 
and if convicted is punishable by the death penalty (U.S. Department of 
State, 2010). 
The substantial variability among drug use patterns and drug 
enforcement laws across the world creates significant hurdles for 
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researchers attempting to study the vulnerable population of drug users. 
However, given the substantial contribution of substance misuse to 
individual and societal harm, it is essential that researchers continue 
to study the multiple aspects of substance use and misuse. Substance use 
research raises a unique set of ethical challenges that can interfere 
with the efforts of researchers to study illicit drug users. It is 
important for researchers to acknowledge these challenges and develop 
novel methods and designs to protect vulnerable populations participating 
in research and assure that this much needed research is being performed. 
Studying these populations helps researchers to understand the underlying 
causes of drug use behavior and develop interventions to minimize harm 
from illicit drug use. The inclusion of illicit drug users, often 
considered vulnerable participants, in research presents several 
increased risks that must be addressed in study protocols. These risks 
can prolong and intensify ethical review processes. This article 
discusses both the perceived and actual risks to illicit drug users 
participating in research, as well as the safeguards researchers can 
utilize to mitigate these risks. A case study is provided to illustrate 
the high level of scrutiny of study protocols that involve the 
participation of illicit drug users and its effect on recruitment. 
Heading level 1:
Risks to Illicit Drug Users Participating in Research
Major ethical challenges exist for substance use research, and many 
of these challenges continue to be unresolved (UNODC, 2004). Significant 
issues exist in several areas, including the capacity to give consent; 
limits to confidentiality; protection from legal hazards; and researcher 
training and understanding of the political, social, and economic 
settings in which their work is conducted (UNODC, 2004). 
Heading level 2:
Informed Consent and Its Limits 
There are multiple ethical concerns in drug use research about the 
ability of individuals using illicit drugs to provide informed consent. Au
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Valid informed consent requires participant comprehension and 
voluntariness (National Commission for the Protection of Human Subjects 
of Biomedical and Behavioral Research, 1979). Researchers often question 
the ability of drug users to give informed consent because the nature of 
addiction is such that potential participants may be intoxicated or 
experiencing withdrawal during the informed consent process, which might 
impede their comprehension and decision making (Anderson & DuBois, 2007; 
College on Problems of Drug Dependence, 1995). However, these concerns 
may be overstated. Two studies examining the informed consent process of 
PWIDs being recruited into HIV vaccine trials showed that PWIDs 
adequately understood the consent process (Harrison, Vlahov, Jones, 
Charron, & Clements, 1995) and performed as well on tests of 
comprehension as other non-substance-using participants (MacQueen et al., 
1999). There is currently no systematic research on the impact of acute 
intoxication during the process of obtaining informed consent (Aldridge & 
Charles, 2008). Many researchers in the area of addiction and substance 
use acknowledge that in some situations, addiction impairs capacity, but 
it does not fully eliminate it (Bell & Salmon, 2011; Carter & Hall, 
2008). Furthermore, if the intended goal of the research study involves 
frequently intoxicated individuals, then it can be argued that 
recruitment of such participants is preferable for reasons of validity 
(UNODC, 2004). Substance use researchers must therefore consider several 
ethical questions, including whether intoxication is an absolute 
exclusion criterion; how to determine the extent of intoxication, and how 
reliable that determination is; how to handle participants who are 
intoxicated but lucid; how to determine the judgment of an intoxicated 
participant; and when proxy consent might be appropriate (UNODC, 2004). 
Other ethical concerns related to informed consent in research on 
illicit drug use exist beyond the question of comprehension and capacity. 
Most research protocols include policies for situations that require 
mandated reporting, such as suicidality, homicidality, and child abuse 
and endangerment. However, potential research participants are not always 
informed about these policies. McCrady and Bux (1999) surveyed 91 
researchers funded by the National Institute on Alcohol Abuse and 
Alcoholism and the National Institute on Drug Abuse, and found that 
participants were informed about these policies in only half the studies. Au
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Confusion and lack of consensus exist on the need to inform participants 
of the limits of confidentiality. In situations in which participants 
pose a high risk for harm to themselves or others, ethics review boards 
require researchers to inform participants of the limits of 
confidentiality in the consent form (Check, Wolf, Dame, & Beskow, 2014; 
McCrady & Bux, 1999; Sieber, 1994). However, disclosure of these 
safeguards may result in decreased quality of data, with participants 
withholding pertinent information or withdrawing from the study, 
therefore compromising the validity of findings.
Heading level 2:
Confidentiality and Protection From Legal Hazards
It is critical that researchers protect the privacy of study 
participants and the confidentiality of all sensitive information that 
they provide. Many types of illicit drug use or prescription drug misuse 
are illegal, as are many activities related to drug use, such as driving 
while intoxicated, selling illicit drugs or diverting prescription drugs, 
and violence and crime while using drugs or in an attempt to finance drug 
use. In most places in the world, study participants could face criminal 
charges if study data were linked to individuals by law enforcement. In 
the United States, a Certificate of Confidentiality (COC) can be obtained 
to assure confidentiality of study participants, as described below. 
However, in all other countries of the world in which a COC does not 
exist, the situation is much less clear (UNODC, 2004). Even when 
protective measures are taken to ensure participant confidentiality, in 
some countries researchers may be compelled by the courts to provide 
study information to law enforcement. The ability of a researcher to 
protect the anonymity of participants and confidentiality of the 
information is paramount for substance use research; however, the ability 
of the researcher to maintain confidentiality is often limited by the 
regulatory frameworks governing the research (Small, Maher, & Kerr, 
2014). Unlike physician–patient and attorney–client relationships, the 
researcher–participant relationship is not privileged, and therefore is 
not provided the same protections for absolute confidentiality (Stone, 
2002). In the absence of privilege, a participant might be reluctant to Au
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participate or decline participation altogether. In those situations, the 
loss of research participation can result in a significant loss for 
society, particularly for the vulnerable population being studied.
Heading level 2:
Researchers’ Understanding of Political, Social, and Economic Settings
The ethical challenges facing substance use researchers can be 
amplified in situations where researchers are exploring drug use across 
different cultures, particularly in developing countries where there is 
little tradition of conducting research, and ethical institutions and 
review processes are not well established (UNODC, 2004). Drug use 
research has primarily been developed in industrialized nations such as 
the United States and Great Britain, both of which have significant 
societal resources to devote to this research. Substance use research 
therefore developed from Western biomedical models, and ethical 
challenges will increase as the research extends beyond these models and 
settings. International collaboration can therefore help to resolve these 
issues, and will allow substance use researchers to view drug use through 
multiple lenses.
Heading level 2:
The Role of Ethics Review Boards
Research ethics boards (REBs) and institutional review boards 
(IRBs) were first developed in response to the ethical challenges of 
basic and clinical research. However, the predominance of the biomedical 
research model within review frameworks can make it difficult for REBs 
and IRBs to conceptualize the risks unique to social science research 
(Small et al., 2014). Their lack of familiarity with social sciences 
research can result in overemphasis on the biomedical approach to ethics 
review, while overlooking or failing to understand the complexities of 
community-based research (Malone, Yerger, McGruder, & Froelicher, 2006; 
Souleymanov et al., 2016).
Research focusing on controversial public health issues such as 
illicit drug use, human trafficking, and illegal arms trade requires the Au
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collection of sensitive information from participants who may be engaged 
in unlawful activity. There is considerable agreement that research on 
these issues is of great prospective value to society, because it has the 
potential to decrease the individual and societal harms of illegal 
activity. However, REBs and IRBs frequently raise concerns that these 
populations, which could be considered vulnerable, are at increased risk 
for coercion in research and therefore require special protection (Office 
for Human Research Protections, 2010). The Common Rule, which guides IRBs 
in the United States, states: 
Inset quote:
When some or all of the subjects are likely to be vulnerable to 
coercion or undue influence, such as children, prisoners, 
individuals with impaired decision-making capacity, or economically 
or educationally disadvantaged persons, additional safeguards have 
been included in the study to protect the rights and welfare of 
these subjects. (U.S. Department of Health and Human Services, 
2018, 46.111(b))
The vagueness of “additional safeguards” places a heavy burden on 
researchers and ethics review boards who may not know exactly how to 
accomplish the goal of protecting these research participants, minimizing 
institutional liability (Anderson & DuBois, 2007). It is therefore not 
surprising that studies submitted to REBs or IRBs for drug use research 
often undergo intense scrutiny (Bell & Salmon, 2011). 
However, protectionist concerns are often overstated (Anderson & 
DuBois, 2007; Small et al., 2014). Well-intentioned attempts to protect 
participants may markedly hinder research and severely impede their 
recruitment and participation in important research. This results in 
researchers’ inability to obtain information that is actually of 
potential benefit to individual participants, their communities, and 
society as a whole (Anderson & DuBois, 2007; Bell & Salmon, 2011). 
Greater involvement of individuals from the affected community of drug 
users in the ethics review process can help to correct some of these 
issues (Bell & Salmon, 2011; Small et al., 2014). Often ethics board 
members have little understanding of the realities of drug users’ lives 
(Bell & Salmon, 2011), and therefore, representation from drug user Au
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communities as advisory members in the ethics review process could 
improve understanding (Australian Injecting and Illicit Drug Users 
League, 2010). 
Heading level 2:
Additional Safeguards to Protect Illicit Drug Users Participating in 
Research
Researchers can apply several additional safeguards to protect the 
confidentiality of illicit drug users participating in research, and the 
sensitive data they provide. In the United States, researchers can obtain 
a COC from the National Institutes of Health. A COC protects researchers 
and their institution from state and federal subpoena, thereby preventing 
researchers from involuntary disclosure of participants’ identities. All 
illicit drugs users are committing federal crimes and therefore are at 
risk for prosecution if their identities are disclosed. A COC provides 
additional assurance to individuals who participate in illegal behaviors 
that their confidentiality will be maintained. However, the full extent 
of protection that the COC offers has yet to be determined (Anderson & 
DuBois, 2007; Duval & Salmon, 2004). In today’s political climate, in 
which historical precedents are continually challenged, it is unclear how 
far a COC’s protections would extend. In theory, the COC protects the 
researchers’ documents, servers, and email accounts from the legal 
process of discovery. It is important to note that a COC protects the 
research team from involuntary disclosure, but does not prohibit them 
from voluntary disclosure. Researchers are not prevented from voluntarily 
disclosing situations, such as child abuse or subjects’ intent to harm 
themselves or others. 
Researchers working with vulnerable populations have ethical and 
legal obligations to protect the identity of their participants as well 
as any sensitive information they uncover during their study. 
Historically, this information was preserved on paper and stored in a 
locked cabinet. When study-related documents were transmitted they were 
mailed using the postal service. But in today’s high technological age, 
data may be collected on iPhones and iPads, transferred to PCs or MACs, 
and emailed or downloaded; thus, the data are at risk for interception or 
access by unauthorized persons (hacking). All researchers must be aware Au
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of the heightened security needed to protect the identity of their 
subjects and the sensitive data they provide. In order to minimize risk 
of unauthorized access (hacks), researchers must take extra precautions 
to ensure the safe collection and transfer of sensitive data. Every step 
of the research process must be scrutinized to ensure that information 
cannot be discovered. The institution’s information technology department 
can provide detailed assistance to researchers concerned about the 
handling of sensitive data. Many commonly used research applications and 
software packages lack the necessary safety parameters to ensure 
protection of sensitive data. For example, iPhones should not be used to 
record interviews, because third-party apps on an iPhone can be 
subpoenaed to obtain the audio files. SurveyMonkey©, a common research 
tool, should not be used to obtain information about illegal activity 
because the company could be subpoenaed to release the Internet protocol 
addresses of the individuals participating in the survey, which could 
then be used to identify participants. All data collected should be 
stored on a secure server, the “locked cabinet” of the Information Age. 
All audio files and transcriptions should be encrypted and sent via safe 
file transport protocol as part of a secure shell protocol. All these 
extra safeguards are valuable in their added ability to protect 
participant confidentiality. However, the process to secure these 
additional safeguards is often protracted, resulting in substantial 
consumption of the researchers’ time and budget. Furthermore, access to 
advanced technology and software is limited to individuals in 
institutions in developed countries. Researchers conducting field 
research in developing countries may lack the resources necessary to 
protect sensitive information from legal discovery. 
Heading level 1:
Case Study
To illustrate the many challenges researchers and ethics review 
boards face when attempting to study individuals using illicit drugs, we 
present the following case study. The primary investigator (PI) in this 
case was a doctoral candidate exploring the use of medical cannabis for 
pediatric epilepsy. The study’s research approach was a qualitative 
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description design, and the study protocol included the use of one-to-one 
interviews with parents administering medical cannabis to their child or 
dependent for the relief of seizures. Because cannabis remains a 
federally prohibited drug, participants in this study risked federal 
prosecution, even when using the drug in accordance with their state’s 
laws. Participants in this study were distributing a Schedule 1 drug to a 
minor, and federal prosecution could result in loss of custody of the 
child and up to 10 years of incarceration. Therefore, risk of involvement 
in this study was not solely limited to individuals’ participation in the 
study, but extended to other family members. The ability of the research 
team to protect the confidentiality of participants was critical, given 
the increased risk to participants and their families. Throughout the 7-
month IRB review and approval process, the study’s protocol was 
scrutinized and important modifications were required to ensure the 
confidentiality of the participants in the study. 
First, the PI obtained a COC from the National Institute of Nursing 
Research. In this case, the COC would protect the study’s researchers and 
institution from federal subpoena, should the U.S. Department of Justice 
seek to prosecute the individuals participating in the study or those 
distributing medical cannabis to them. The COC would protect the PI from 
involuntary disclosure; however, as stated prior, it would not protect 
the PI from voluntary disclosure. Because medical cannabis for the 
treatment of seizure activity remains illegal in 20 states, its 
distribution to a minor in those states would be considered child abuse. 
Therefore, if the PI inadvertently interviewed individuals giving their 
child cannabis in states where its use was not legal, the research team 
would be mandated by law to report those individuals for child abuse, 
based upon their state’s definition of the crime. In an effort to 
minimize the risk of inadvertently identifying individuals unlawfully 
using cannabis, the research team consulted the institution’s general 
counsel. The general counsel provided advice and guidance to the research 
team throughout the IRB application and review process. The additional 
feedback from the general counsel resulted in additional safeguards to 
protect the confidentiality of the participants. Following the 
recommendation of general counsel and the IRB, the research team 
highlighted these eligibility requirements multiple times in the Au
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recruitment flyer and consent form. The limits to confidentiality 
associated with mandated reporting of child abuse were clearly detailed 
(in bold) in the consent form:
There are two instances in which confidentiality may be broken:
Numbered list:
1. If the primary investigator is subpoenaed by the Federal Government to 
release the identity of the participants. 
2. If the primary investigator observes any child abuse or neglect during 
the interviews. If child abuse or neglect is observed the investigator 
is mandated to report that to child services within the individual 
state.
To ensure that potential participants correctly understood the laws 
in their states, an Internet link was provided in the recruitment flyer 
directing potential participants to a website that clearly identifies the 
law on medical cannabis use for each individual state. To volunteer to 
participate in the study, the participant was instructed to email the PI. 
The PI then responded with a question as to whether or not potential 
participants were using medical cannabis in accordance with their state 
laws. If the potential participants were not, they were directed to cease 
any further correspondence and their email address was deleted from the 
server. This extra screening measure was in place to avoid inadvertent 
discovery of participants using medical cannabis illegally for their 
child.
These extra safeguards decreased the risk of inadvertently 
identifying individuals using cannabis illegally, and there were no 
instances in which the PI observed child abuse. However, the low level of 
response to outreach about the study among online medical cannabis 
advocacy communities who were initially enthused about the study led the 
research team to posit that risks presented in the consent form may have 
deterred eligible participants from participating in the study. It is 
difficult to assess whether the presentation of risks in the consent form 
affected recruitment, or if the risks themselves deterred individuals 
from participation.
Recruitment for the study was affected by several factors. The most 
important factor was the changing federal policy on prosecution of legal Au
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medical cannabis users. The study protocol was designed during the Barack 
Obama administration, but following a lengthy IRB process the protocol 
was not initiated until the Donald Trump administration. Changes in 
leadership in the U.S. Department of Justice (USDOJ) resulted in 
significant policy changes regarding the federal prosecution of medical 
cannabis users, which may have had a substantial impact on recruitment 
for this study. On January 4, 2018, Attorney General Jefferson Sessions 
rescinded previous USDOJ memos that specified federal protections for 
individuals using cannabis in accordance with state laws (Sessions, 
2018). This action created significant ambiguity and uncertainty for many 
medical cannabis users. Many potential volunteers for this study declined 
to participate due to fear of federal prosecution. During snowball 
referrals, the PI was told by one participant that other potential 
volunteers would not participate in the study due to the actions of the 
Attorney General. The PI had anticipated a federal policy change with the 
appointment of Attorney General Sessions, and was aware that this policy 
change could significantly jeopardize recruitment efforts. The PI was 
eager to begin recruitment before any policy change was initiated; 
however, the protracted IRB review process resulted in the delay of 
recruitment of almost 7 months, which greatly affected the study.
Recruitment for this study was also greatly hampered by the 
changing approach in the USDOJ. Despite initial enthusiasm for the study 
from marijuana advocacy groups, recruitment resulted in only three 
interview participants. It is difficult to assess whether the 
presentation of risk in the consent form deterred participation, or 
whether federal policy changes at the USDOJ had a stronger impact on 
potential participants’ willingness to participate. It is noted that at 
least one comment on the recruitment postings indicated suspicion that 
the PI was actually a federal agent. Even with the multiple additional 
safeguards in place, the investigator was unable to recruit an adequate 
number of participants, and therefore the study’s research design had to 
be modified. The investigator concluded that despite enhanced IRB 
scrutiny and the addition of multiple safeguards, potential participants 
still did not trust the research process. How researchers will address 
the lack of trust in the current political climate remains an important 
question for all researchers studying illicit drug use and other criminal Au
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activities. 
Heading level 1:
Discussion 
REBs and IRBs have been subjected to increasing criticism and 
scrutiny (Abbott & Grady, 2011; Burman et al., 2003; Phillips, 1996). 
Critics of the current REB and IRB review system describe it as outdated 
and ill-equipped to handle the needs of current day researchers (Abbott & 
Grady, 2011; Maschke, 2012). There continues to be substantial 
variability among REBs and IRBs (Abbott & Grady, 2011; Kimberly, Hoehn, 
Feudtner, Nelson, & Schreiner, 2006; Larson, DeBasio, Mundinger, & 
Shoemaker, 1995). Variability from one ethics review board to another can 
be problematic when differences in assessments of risk and application of 
regulations exist, which can threaten the scientific merit and 
contributions of a study by decreasing productivity of the research team 
and increasing costs without enhancing participant protection (Abbott & 
Grady, 2011). The full impact of REB and IRB review on the protection of 
human research participants is difficult to measure. However, the failure 
of REBs and IRBs to protect human subjects can have serious and 
significant consequences to human research participants as well as 
research institutions and the researchers (Gelsinger v. Trustees of the 
University of Pennsylvania, 2000). REBs and IRBs are often charged with 
the difficult challenge of ensuring participant protection through 
meticulous review of study protocols, while maintaining efficiency to 
keep up with the pace of 20th century research. 
The addition of safeguards to the standards of protection of human 
subjects, while beneficial to the confidentiality of participants, can be 
timely, costly, and burdensome to the research team. Overly burdensome 
study protocols can undermine the ability of investigators to acquire 
knowledge that is sorely needed to address health-related issues and 
social determinants of health outcomes, as well as the development of 
informed health policy. Advanced software designed to protect sensitive 
data often has a higher cost than conventional software and is limited to 
those with access in well-established research institutions in developed 
nations. Applications for the COC and ethics approval can be prolonged Au
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due to the need to address the increased risk to participants. This delay 
can prevent the collection of time-sensitive data and can hinder efforts 
to examine current issues. The many extra steps needed to ensure that 
data collection is secure can be onerous for both participants and the 
research team. 
Despite these safeguards, lack of trust, especially within the 
current political climate, can still deter participation in research. 
Trust is an important factor in the willingness of individuals to 
participate in research, particularly minority populations (Corbie-Smith, 
Thomas, & George, 2002; Millon-Underwood, Sanders, & Davis, 1993; 
Oransky, Fisher, Mahadevan, & Singer, 2009; Sengupta et al., 2000). 
Illicit drug users have expressed fear that participation in research 
could result in arrest, and that fear of getting caught or “busted” was 
perceived as a significant barrier to recruitment (Oransky et al., 2009). 
Researchers studying illicit drug users will have to take extra steps to 
secure trust with potential participants. Potential participants must be 
provided complete and honest information about the study, and about 
specifics regarding the extent and limits of confidentiality (Oransky et 
al., 2009). 
Heading level 1:
Conclusions 
The value and importance of information gained through the study of 
vulnerable populations outweighs the burden on research teams and ethics 
review boards. Individuals who participate in criminal or illegal 
behaviors such as illicit drug use, prostitution, illegal entry into a 
country, and human trafficking are susceptible to multiple physical, 
mental, and social health risks, as well as criminal prosecution, and we 
need to know how best to address these problems. Nursing research has a 
proud history of studying vulnerable populations. Those studies provide 
insight into the experiences of the individuals who live in the obscure 
corners of our society. The importance of research on the health of 
marginalized populations cannot be overstated. This work must continue, 
and at the same time, we must continue to protect these individuals to 
the best of our ability through diligent attention to sound research Au
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methods. 
Please gray-box Clinical Resources
Heading level 1: 
Clinical Resources
 National Institute on Drug Abuse. Addiction science. 
https://www.drugabuse.gov/related-topics/addiction-science  National Institute on Drug Abuse. Drugs, brains, and behavior: The 
science of addiction. https://www.drugabuse.gov/publications/drugs-
brains-behavior-science-addiction/preface  National Institutes of Health, Office of Extramural Research. 
Certificates of confidentiality. 
https://humansubjects.nih.gov/coc/index
Heading level 2:
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